The Top 3 Gene-Editing Stocks to Own Right Now

June 30, 2021 www.tradewins.com Other Exciting News One Simple Step Believe it or not… One Simple Step That takes less than 2 minutes to do… Has made it possible for traders of every level… To earn consistent profits every single year for 20 consecutive years… despite 3 market crashes, numerous corrections, and loads of sideways chop. How can something so powerful be so simple to learn? See for yourself… One Simple Step To Better Trade Results My name's Chuck Hughes and I've won highly competitive trading championships a total of 10 times… probably more times than anyone else in history… with audited annual returns as high as 200%, 300%, even 330%. And the secret to my success starts with One Simple Step I take; but most traders don't know about. Click Here Now… Learn my simple 1-step profit secret for FREE! If you're like most folks I know, you'll be amazed when you see the results. Best Regards, Chuck Hughes Recent Articles The Top 3 Gene-Editing Stocks to Own Right Now by Ian Cooper Spreading Techniques by Jon Najarian Keith's Outlier Watch List by Keith Harwood TradeWins Author Team     Tomorrow, you could begin doubling your account every single month starting with one letter. The letter will come from a 20-year trading professional named Ian Cooper. He says, "In 2017, following my trades you would be doubling even tripling your account some months. Let me show you how." He will show you exactly what to do... and he'll give you the blueprint for just $1. Get Daily Trade Alert Now About TradeWins Inside Trading Newsletter Webinars Videos Trading Strategy Options Futures Forex Day Trading Subscription Services E-Books Customer Satisfaction Survey 2020 The Top 3 Gene-Editing Stocks to Own Right Now by Ian Cooper Gene-editing has become one of the top investing buzzwords. All as gene editing show progress in identifying and potentially curing diseases. Even more impressive, according to Interesting Engineering, "researchers have already identified DNA errors as the cause of nearly 7,000 diseases. Thankfully, the growing world of genome editing could be the 'spell-checker' needed to detect and eventually fix these." In short, everyone should be excited about the potential here. Gene Editing Stock No. 1 – Intellia Therapeutics (NTLA) Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The NTLA stock just exploded after releasing "interim data from the Phase 1 trial of its collaboration with Regeneron on an experimental therapy for transthyretin amyloidosis (ATTR) – a protein misfolding disorder," as noted in a company press release. "The data showed that for the six people that received a single 0.3 mg/kg dose of NTLA-2001, there was an 87% mean reduction in serum TTR, while there was a maximum 96% serum TTR reduction following a month's treatment," the company added. Read More   Spreading Techniques by Jon Najarian There is far more to options than just buying a put or a call and waiting for the market to move. In fact, once retail investors learn the ropes, they can quickly become adept at using basic strategies to control risk and enhance potential profits. The options plays you execute will depend largely upon two things: your risk tolerance and your portfolio goals. Risk and reward are directly proportional – the higher one is, the higher the other is as well. If you have a high risk-tolerance and your aim is to make 200 percent on your money, then you're probably going to follow and aggressive option strategy. If your risk tolerance and your investment goals are more middle-of-the-road – meaning, you'll be satisfied with say, a 30 percent return and don't want to risk more capital than is absolutely necessary – then you're likely to adhere to a more conservative spreading technique. Spreading, which involves selling one type of option and buying another, is one of the most common ways to create positions that match your outlook for a given stock or index and limit your risk. Depending on the type of strategy you choose, these spreads can limit your upside potential as well. But the trade-off of capping your risk, in return for a limit on the upside, usually is one that many investors are willing to make. Consider, for example, buying an out-of-the-money (OTM) call at the 55 strike with a $5 premium that's two months out and selling a nearby OTM call at the 65 strike for $2. The worst thing that can happen, no matter how much the market moves, is you might lose $3, the difference between the $5 you paid and the $2 you received. Read More Keith's Outlier Watch List by Keith Harwood Keith's Outlier Watch List is actually comprised of two separate lists…   Candidates for our Big League Options portfolio of stocks trending above other stocks in the NASDAQ 100… average open profit 128.5%. Candidates for our Home Run Swing Trader, including the trigger price for entry… average profit 239.45% in less than 30 days. Click Here to check out one of this week's recommendations. Read More   www.tradewins.com                © Copyright 2021 TradeWins.com. All rights reserved. TradeWins Publishing, 22C New Leicester Hwy, #117, Asheville, NC 28806 Email: support@iss-trading.com   |   Phone: 888-233-1431   |   Fax: 888-258-4938   PLEASE READ: Auto-trading, or any broker or advisor-directed type of trading, is not supported or endorsed by TradeWins. For additional information on auto-trading, you may visit the SEC's website: All About Auto-Trading, TradeWins does not recommend or refer subscribers to broker-dealers. You should perform your own due diligence with respect to satisfactory broker-dealers and whether to open a brokerage account. You should always consult with your own professional advisers regarding equities and options on equities trading. 1) The information provided by the newsletters, trading, training and educational products related to various markets (collectively referred to as the "Services") is not customized or personalized to any particular risk profile or tolerance. Nor is the information published by TradeWins Publishing ("TradeWins") a customized or personalized recommendation to buy, sell, hold, or invest in particular financial products. The Services are intended to supplement your own research and analysis. 2) TradeWins' Services are not a solicitation or offer to buy or sell any financial products, and the Services are not intended to provide money management advice or services. 3) Past performance is not necessarily indicative of future results. Trading and investing involve substantial risk. Trading on margin carries a high level of risk, and may not be suitable for all investors. Other than the refund policy detailed elsewhere, TradeWins does not make any guarantee or other promise as to any results that may be obtained from using the Services. No person subscribing for the Services ("Subscriber") should make any investment decision without first consulting his or her own personal financial adviser, broker or consultant. TradeWins disclaims any and all liability in the event anything contained in the Services proves to be inaccurate, incomplete or unreliable, or results in any investment or other loss by a Subscriber. 4) You should trade or invest only "risk capital" – money you can afford to lose. Trading stocks and stock options involves high risk and you can lose the entire principal amount invested or more. 5) All investments carry risk and all trading decisions made by a person remain the responsibility of that person. There is no guarantee that systems, indicators, or trading signals will result in profits or that they will not produce losses. Subscribers should fully understand all risks associated with any kind of trading or investing before engaging in such activities. 6) Some profit examples are based on hypothetical or simulated trading. This means the trades are not actual trades and instead are hypothetical trades based on real market prices at the time the recommendation is disseminated. No actual money is invested, nor are any trades executed. Hypothetical or simulated performance is not necessarily indicative of future results. Hypothetical performance results have many inherent limitations, some of which are described below. Also, the hypothetical results do not include the costs of subscriptions, commissions, or other fees. Because the trades underlying these examples have not actually been executed, the results may understate or overstate the impact of certain market factors, such as lack of liquidity. Simulated trading services in general are also designed with the benefit of hindsight, which may not be relevant to actual trading. In addition, hypothetical trading does not involve financial risk, and no hypothetical trading record can completely account for the impact of financial risk of actual trading. TradeWins makes no representations or warranties that any account will or is likely to achieve profits similar to those shown. 7) No representation is being made that you will achieve profits or the same results as any person providing testimonial. No representation is being made that any person providing a testimonial is likely to continue to experience profitable trading after the date on which the testimonial was provided, and in fact the person providing the testimonial may have experienced losses. 8) The author experiences are not typical. The author is an experienced investor and your results will vary depending on risk tolerance, amount of risk capital utilized, size of trading position and other factors. Certain Subscribers may modify the author methods, or modify or ignore the rules or risk parameters, and any such actions are taken entirely at the Subscriber's own election and for the Subscriber's own risk.

If you wish to stop receiving our emails or change your subscription options, please Manage Your Subscription
TradeWins Publishing, 528 North Country Rd., St. James, NY 11780